Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 12/20 | 1.00 |
| ▸ | TACR1 | P25103 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20149105 | 0.88 | RORC (1.00) | RORC | |
| SCHEMBL20149104 | 0.83 | RORC (0.71) | RORCTACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL23713117 | 0.81 | RORC (1.00) | RORCTACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20149107 | 0.76 | RORC (1.00) | RORCTACR3CCR5 | |
| SCHEMBL23713050 | 0.75 | RORC (1.00) | RORC | |
| SCHEMBL23713020 | 0.73 | RORC (1.00) | RORCCCR5 | |
| SCHEMBL15751781 | 0.73 | RORC (0.57) | RORCTACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20139701 | 0.72 | RORC (0.65) | RORCCCR5 | |
| SCHEMBL20139698 | 0.72 | RORC (0.65) | RORCCCR5 | |
| SCHEMBL20149057 | 0.70 | RORC (1.00) | RORCTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078186-B2 | ROR γ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078186-B2 | ROR γ modulators | RORB, RORC, RORA | RORC 2/4885TACR1 1939/4885CYP3A4 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.